A disinfecting, sanitizing, virucidal, antibacterial or mold-inhibition claim usually requires proof against defined organisms and strict label directions such as wet contact time
Tirzepatide is the only licenced GLP-1/GIP co-agonist for obesity, with several more GLP-1/GIP co-agonists in development [15]
A snapshot of childrens health in Australia Harriet Hiscock, Principal Fellow, Department of Paediatrics, The University of Melbourne, Murdoch Childrens Research Institute This article was originally published on The Conversation
It is typically recommended for adults with obesity, who are overweight, or have weight-related health conditions
The analysis highlights a significant opportunity to reduce healthcare costs for employers and enhance overall workforce health through a comprehensive obesity management program that includes GLP-1 medications